CHARLOTTESVILLE, Va., April 22, 2020 /PRNewswire/ — Biovista, a privately-held AI / bioscience firm best known for drug repositioning, has identified four treatments – two prescription drugs and two over-the-counter compounds — to counter key symptoms of COVID-19. “Drug AI helps find that needle in the haystack, and we are optimistic that we have found four … Read More
News
Business Development Agent in Japan
Biovista is pleased to announce the appointment of a Business Development Agent in Japan. Based in Tokyo, our BD Agent will serve Biovista customers and collaborators throughout Japan. Our agent will focus on Biovista’s new therapy development services and will serve as the main contact point for our Japanese customers. Additionally, our Agent will support … Read More
High Throughput Layout and Copy Paste
The latest version of Biovista Vizit introduces two much requested features: A new High Throughput Layout, and A new Copy/Paste mechanism to transfer named Entities in and out of Vizit. Here’s a quick rundown of the new features: High Throughput Layout Biovista Vizit is frequently used for systematic exploration of a biomedical domain. For example, … Read More
Biovista in World’s Top 20 AI Drug Development Companies
Biovista has been selected as one of the top-20 AI Drug Development companies in a recent article in Forbes View the article here: https://www.forbes.com/sites/yiannismouratidis/2018/12/16/the-rising-star-companies-in-ai-drug-development/
Biovista signs EU-IMI2 research agreement to advance neurotoxicity de-risking in preclinical drug discovery
Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative (IMI). Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Together with EFPIA members … Read More